Content
Search
Navigation
Sitemap

About us
Our people
- Our people
- Board of directors
Portfolio
Sustainability
News and Insights
Investors
Contact

News

Show

Sustainability
Financial
Operating News

news from

all companies
Syncona
all Cell therapy companies
Autolus
Achilles Therapeutics
Quell Therapeutics
Resolution Therapeutics
Clade Therapeutics
all Gene therapy companies
Freeline Therapeutics
AGTC
SwanBio Therapeutics
Purespring Therapeutics
all Biologics companies
Anaveon
all Small molecule companies
OMass Therapeutics
Kesmalea Therapeutics
Mosaic Therapeutics

10.05.23

Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens

Cell therapy
Achilles Therapeutics

10.05.23

Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

Cell therapy
Achilles Therapeutics

25.04.23

Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status

Operating News
Cell therapy
Achilles Therapeutics

07.03.23

Achilles reports Q3 2022 Financial Results and Business Highlights

Operating News
Cell therapy
Achilles Therapeutics

20.12.22

Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Operating News
Cell therapy
Achilles Therapeutics

06.12.22

Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022

Operating News
Cell therapy
Achilles Therapeutics

Sign-up for company news alerts

Get the latest RNS, company news, share price information and results from Syncona

RNS alerts
Company alerts

Syncona Investment Management Limited
2nd Floor
8 Bloomsbury Street
London
WC1B 3SR

contact@synconaltd.com

About us
Our people
Portfolio
Sustainability
News and Insights
Investors
Contact

Copyright © Syncona 2023
Accessibility
Privacy & cookies
Employee privacy notice
Third party privacy notice
Regulatory publications
Modern Slavery Statement

Syncona Limited is registered in Guernsey no. 55514, registered office Arnold House, PO Box 273, St Julian’s Avenue, St Peter Port, Guernsey GY1 3RD.
Syncona Investment Management Limited is registered in England no. 10497864, 8 Bloomsbury Street, London WC1B 3SR and is authorised and regulated by the FCA. Syncona Limited is managed by Syncona Investment Management Limited.

Designed & built by SampsonMay

About us
Our people
- Our people
- Board of directors
Portfolio
Sustainability
News and Insights
Investors
Contact

GBX 154.40

Change: +2.40 (+1.58%)

Search

Search